A new study suggests that a group of medications originally designed to treat diabetes may also help prevent and treat addiction.
Researchers at Washington University School of Medicine in St. Louis found that drugs known as GLP‑1 receptor agonists appear to reduce the risk of substance-use disorders and serious harms linked to addiction. The research was published in The BMJ and analyzed health records from hundreds of thousands of patients.
Substance-use disorders are a major global health problem. Millions of people struggle with addiction to alcohol, nicotine, opioids, and other drugs. These conditions can lead to severe health problems, including overdose, mental illness, and early death. In many cases, treatment options are limited.
Some medications can help with certain addictions, such as nicotine replacement therapy for smoking or medications that help people stop using opioids. However, most available treatments focus on only one specific substance. There are very few medicines that can help people struggling with multiple addictions at the same time.
GLP‑1 receptor agonists are a relatively new class of drugs that were first developed to treat type 2 diabetes. These medications help control blood sugar levels by improving the body’s response to insulin and slowing digestion so that sugar enters the bloodstream more gradually.
In recent years, some of these drugs, including semaglutide and tirzepatide, have become widely known because they can also help people lose weight. As a result, their use has grown rapidly around the world.
Doctors and researchers began noticing something unusual among patients taking these medications. Some people reported that after starting GLP‑1 drugs they lost interest not only in food but also in alcohol, cigarettes, and other addictive substances.
These reports led scientists to wonder whether the medications might affect the brain systems that control craving and reward.
To investigate this possibility, researchers led by Dr. Ziyad Al‑Aly examined the medical records of 606,434 U.S. veterans who had type 2 diabetes. The study divided the participants into two groups.
The first group included people who did not have a history of substance-use disorder when they started treatment for diabetes. The second group included patients who already had a substance-use disorder.
The researchers compared patients taking GLP‑1 receptor agonists with those taking another type of diabetes medication known as SGLT2 inhibitors. These medicines also help control blood sugar but work through a different biological pathway.
By comparing the two groups, scientists could better understand whether GLP‑1 drugs were associated with changes in addiction risk.
The researchers followed the participants’ health records for up to three years. Among the 524,817 individuals who did not already have a substance-use disorder, the study tracked whether they developed addiction to alcohol, cannabis, cocaine, nicotine, opioids, or other substances during the study period.
The results showed a clear pattern. People taking GLP‑1 medications had a lower risk of developing substance-use disorders across all major substances studied. Overall, the risk was about 14 percent lower compared with those taking non‑GLP‑1 diabetes medications.
The researchers also looked at each type of addiction separately. The risk of developing alcohol-use disorder fell by about 18 percent. Cannabis addiction dropped by 14 percent. Cocaine and nicotine addiction each decreased by about 20 percent. The largest reduction was seen with opioid addiction, which fell by about 25 percent.
In practical terms, this meant that for every 1,000 patients treated with GLP‑1 medications, about seven fewer people developed a substance-use disorder compared with those receiving other diabetes treatments.
The second part of the study focused on patients who already had a substance-use disorder when they began diabetes treatment. Among these 81,617 participants, researchers tracked serious outcomes related to addiction, including hospital visits, overdose, death, and suicide-related events.
Again, the results were striking. Patients taking GLP‑1 medications experienced fewer serious addiction-related events. Emergency department visits related to substance use fell by about 30 percent.
Hospitalizations dropped by roughly 25 percent. Overdoses declined by 40 percent, and drug‑related deaths were reduced by about 50 percent over the three‑year period.
This translated into about 12 fewer serious harm events for every 1,000 people treated with GLP‑1 medications.
Scientists believe these effects may occur because GLP‑1 receptors are present in brain regions that regulate reward and motivation. These areas of the brain influence how strongly people crave rewarding experiences such as food, alcohol, or drugs. By acting on these pathways, GLP‑1 medications may reduce the intense cravings that drive addiction.
Dr. Al‑Aly explained that most addiction treatments focus on a specific substance. For example, nicotine patches help people stop smoking, but they do not treat alcohol addiction or drug dependence.
The findings from this study suggest that GLP‑1 drugs may target a deeper biological process that underlies many types of addiction. Instead of treating one substance at a time, these medications may reduce the craving itself.
Researchers sometimes describe patients taking GLP‑1 medications as experiencing a reduction in “food noise,” meaning the constant thoughts about eating that drive overeating. Dr. Al‑Aly suggests the same concept may apply to addiction. The drugs may also reduce what he calls “drug noise,” the persistent mental pull that drives people to seek addictive substances.
The potential impact of these findings could be significant. Millions of people are already taking GLP‑1 medications to treat diabetes or obesity. If these drugs also reduce addiction risk, they could help address two major public health challenges at the same time.
However, the study was observational, meaning it analyzed existing medical records rather than conducting a controlled clinical trial. Because of this, the results cannot prove that the medications directly caused the reduction in addiction risk. Other factors might also contribute to the observed effects.
Even so, the large size of the study and the consistent results across multiple substances make the findings especially intriguing. The research team believes the results strongly support the need for clinical trials specifically designed to test GLP‑1 drugs as treatments for addiction.
If future studies confirm these effects, GLP‑1 medications could represent a new type of addiction therapy that works across many substances rather than targeting just one. This could open the door to a completely different strategy for treating substance-use disorders.
In reviewing the findings, the study provides compelling evidence that GLP‑1 medications may influence the biological systems that control craving and reward. By reducing these signals, the drugs may lower both the risk of developing addiction and the severity of its consequences.
However, because the research relied on observational data and focused on patients with diabetes, further clinical trials will be necessary to confirm whether the same benefits apply to broader populations. If future research supports these findings, GLP‑1 drugs could become an important new tool in the fight against addiction.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies that Mediterranean diet can reduce belly fat much better, and Keto diet could help control body weight and blood sugar in diabetes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
